Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 6% - What's Next?

Key Points

• Monte Rosa Therapeutics shares fell 6% to $13.07, with trading volume down 81% from its average. The stock remains well below its 50-day and 200-day moving averages.
• Despite the decline, analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $28.50; several firms recently reduced targets to $27–$28.
• The company missed quarterly expectations, reporting an adjusted loss of $0.43 per share versus $0.38 expected and revenue of $8.97 million versus $12.91 million. Insiders have sold $1.73 million of stock over the past 90 days, while institutional investors own nearly 80% of shares.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report)'s share price dropped 6% during trading on Tuesday . The stock traded as low as $13.14 and last traded at $13.07. 250,129 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 1,347,425 shares. The stock had previously closed at $13.90.

Analyst Upgrades and Downgrades

GLUE has been the topic of a number of analyst reports. Wells Fargo & Company cut their price objective on shares of Monte Rosa Therapeutics from $29.00 to $27.00 and set an "overweight" rating on the stock in a report on Friday, August 7th. Jefferies Financial Group reiterated a "buy" rating on shares of Monte Rosa Therapeutics in a report on Monday, July 27th. JPMorgan Chase & Co. cut their price target on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an "overweight" rating on the stock in a report on Friday, August 7th. Guggenheim reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Monte Rosa Therapeutics in a research report on Tuesday, August 25th. Finally, Weiss Ratings cut Monte Rosa Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Monte Rosa Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $28.50.

Monte Rosa Therapeutics Price Performance

The stock's 50-day moving average is $17.86 and its two-hundred day moving average is $18.27. The stock has a market cap of $1.12 billion, a P/E ratio of -7.43 and a beta of 1.50.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $8.97 million for the quarter, compared to the consensus estimate of $12.91 million. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. On average, analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.04 EPS for the current fiscal year.

Insider Transactions at Monte Rosa Therapeutics

In other news, insider Sharon Townson sold 6,000 shares of the firm's stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total value of $139,860.00. Following the sale, the insider directly owned 67,845 shares in the company, valued at approximately $1,581,466.95. This trade represents a 8.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jennifer Champoux sold 2,176 shares of the business's stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $19.00, for a total transaction of $41,344.00. Following the transaction, the chief operating officer owned 62,371 shares of the company's stock, valued at approximately $1,185,049. This trade represents a 3.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 79,603 shares of company stock valued at $1,725,081. Company insiders own 6.40% of the company's stock.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of large investors have recently made changes to their positions in GLUE. BlackRock Inc. purchased a new stake in shares of Monte Rosa Therapeutics during the second quarter valued at $165,603,000. Jupiter Topco LLC purchased a new stake in Monte Rosa Therapeutics during the 2nd quarter valued at about $25,965,000. Dimensional Fund Advisors LP increased its holdings in shares of Monte Rosa Therapeutics by 83.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,041,372 shares of the company's stock valued at $17,125,000 after purchasing an additional 473,005 shares during the period. Opaleye Management Inc. acquired a new position in shares of Monte Rosa Therapeutics in the second quarter valued at about $18,029,000. Finally, Janus Henderson Group PLC purchased a new position in shares of Monte Rosa Therapeutics in the first quarter worth about $11,294,000. 79.96% of the stock is owned by institutional investors and hedge funds.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company developing small-molecule medicines designed to selectively eliminate disease-causing proteins. The company uses its proprietary Tunable Molecular Glue (TME) platform to identify molecular glue degraders that redirect the cell's natural protein-degradation machinery toward specific therapeutic targets.

Monte Rosa's research and development programs address areas including autoimmune and inflammatory diseases, as well as cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.